IMWG Conference Series: Reporting from ASH 2022

Leading myeloma experts will discuss the latest myeloma news from the 64th ANNUAL American Society of Hematology Conference.  December 2022
Moderated by IMF Chairman of the Board Dr. Brian G.M. Durie, panelists will include María V. Mateos (University of Salamanca-Salamanca, Spain) and Dr. Thomas Martin (University of CA, San Francisco).
The panel and Dr. Durie will then focus on many abstracts from the following oral presentation sessions from the ASH conference.
0:03:19 - Bispecfic Antibodies
0:16:11 - CAR T Frontline
0:23:01 - Iceland Screening iSTOPMM
0:30:01 - ASCENT & Cesar Trials
0:38:12 - MRD Testing: Ultra sensitive/Mass Spectrometry
0:47:16 - Dex Sparing Combination
For more related ASH 2022 content please visit: www.myeloma.or...
_______________
Improving Lives | Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: / imfmyeloma
Visit our website at: www.myeloma.org
Find us online:
Facebook: @myeloma | / myeloma
Twitter: @IMFMyeloma | / imfmyeloma
Instagram: @imfmyeloma | / imfmyeloma
LinkedIn: / international-myeloma-...
Support the IMF | Donate Now! secure.myeloma...
Category
Nonprofits & Activism
License
Standard KZbin License
In most cases, captions are autogenerated by KZbin.

[@rmcellig]

I'm part of the magnetmm bispecific elranatomab trial. Some side effects do far. You talk about the future. I think the future is getting closer and closer with these new therapies. Tri specific therapies might be on the horizon as well so this is very promising!!

[@karincarlen1614]

Why I havemeyloma imy head